Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

Phase 3

Completed

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Biological: filgrastim

First Posted Date: 2006-07-20

Last Posted Date: 2020-01-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 109

Registration Number: NCT00354744

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States

and more 162 locations

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Leucovorin
Drug: Irinotecan

First Posted Date: 2006-07-20

Last Posted Date: 2011-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00354978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract

Phase 2

Completed

Conditions: Gastrointestinal Cancer
Carcinoma, Neuroendocrine

Interventions: Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2006-07-17

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00353015

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: bevacizumab
Drug: irinotecan
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2006-07-14

Last Posted Date: 2014-07-22

Lead Sponsor: Duke University

Target Recruit Count: 20

Registration Number: NCT00352521

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: Celecoxib
Drug: Cisplatin
Drug: CPT-11
Radiation: Concurrent Thoracic Radiation Therapy

First Posted Date: 2006-06-30

Last Posted Date: 2012-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00346801

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: bevacizumab
Drug: irinotecan

First Posted Date: 2006-06-27

Last Posted Date: 2017-05-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 167

Registration Number: NCT00345163

Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

Phase 2

Completed

Conditions: Rectum Cancer
Colon Cancer

Interventions: Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2006-06-14

Last Posted Date: 2016-07-12

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 35

Registration Number: NCT00336856

Locations: 🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

First Posted Date: 2006-06-12

Last Posted Date: 2017-07-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 291

Registration Number: NCT00335556

Locations: 🇺🇸
Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States

and more 184 locations